Beijing Shurui is a technology company founded by industry elites active in medical equipment in China. Relying on the core technology of a new generation of flexible continuum robotic arms, it runs through the implementation paradigms of various types of clinical minimally invasive surgery, and controls the powerful system design and integration capabilities, and strives to become the first domestic company that can completely independently develop, produce and sell third-generation microsurgery. It is a high-tech enterprise that creates a surgical robotic system, in order to provide hospitals with a complete solution of “preoperative planning-intraoperative operation-postoperative management” integrated intelligent surgery. Recently, it completed the C1 round of financing of several hundred million yuan. This round of financing was led by Shanghai Biomedical Fund, followed by Yuanxing Capital, and the old shareholders of Shurui, such as Medtronic, Shunwei Capital, SDIC China Merchants, and Tianfeng Capital, continued to give full support. China Renaissance acted as the exclusive financial advisor for the transaction.
This article is reproduced from: https://www.itjuzi.com/investevent/13256067
This site is for inclusion only, and the copyright belongs to the original author.